Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E. Mansier O, et al. Among authors: ianotto jc. Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. Am J Hematol. 2018. PMID: 29266414 Free article. No abstract available.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: ianotto jc. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Rey J, et al. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25. Eur J Haematol. 2014. PMID: 24118452 Free PMC article. Clinical Trial.
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Cabagnols X, et al. Among authors: ianotto jc. Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. Leukemia. 2015. PMID: 25212275 No abstract available.
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.
Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, Favier R, Diop MK, Ugo V, Casadevall N, Debili N, Raslova H, Bellanné-Chantelot C, Constantinescu SN, Bluteau O, Plo I, Vainchenker W. Cabagnols X, et al. Among authors: ianotto jc. Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8. Blood. 2016. PMID: 26450985 Free article.
Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.
Mahé K, Luque Paz D, Couturier MA, Chauveau A, Quintin-Roué I, Berthou C, Ugo V, Lippert E, Ianotto JC. Mahé K, et al. Among authors: ianotto jc. Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27. Ann Hematol. 2016. PMID: 26611851 No abstract available.
131 results